These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39010172)

  • 1. Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.
    Fernando F; Andres MS; Claudiani S; Kermani NZ; Ceccarelli G; Innes AJ; Khan A; Rosen SD; Apperley JF; Lyon AR; Milojkovic D
    Cardiooncology; 2024 Jul; 10(1):42. PubMed ID: 39010172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
    Di Lisi D; Madaudo C; Alagna G; Santoro M; Rossetto L; Siragusa S; Novo G
    ESC Heart Fail; 2022 Jun; 9(3):1914-1919. PubMed ID: 35355425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
    Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
    Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.
    Bocchia M; Galimberti S; Aprile L; Sicuranza A; Gozzini A; Santilli F; Abruzzese E; Baratè C; Scappini B; Fontanelli G; Trawinska MM; Defina M; Gozzetti A; Bosi A; Petrini M; Puccetti L
    Oncotarget; 2016 Nov; 7(44):72311-72321. PubMed ID: 27527867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study.
    Chen MT; Huang ST; Lin CW; Ko BS; Chen WJ; Huang HH; Hsiao FY
    Oncologist; 2021 Nov; 26(11):974-982. PubMed ID: 34418220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
    Leong D; Aghel N; Hillis C; Siegal D; Karampatos S; Rangarajan S; Pond G; Seow H
    Heart; 2021 Apr; 107(8):667-673. PubMed ID: 33419879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Rivero-Santana B; Saldaña-García J; Caro-Codón J; Zamora P; Moliner P; Martínez Monzonis A; Zatarain E; Álvarez-Ortega C; Gómez-Prieto P; Pernas S; Rodriguez I; Buño Soto A; Cadenas R; Palacios Ozores P; Pérez Ramírez S; Merino Salvador M; Valbuena S; Fernández Gasso L; Juárez V; Severo A; Terol B; de Soto Álvarez T; Rodríguez O; Brion M; González-Costello J; Canales Albendea M; González-Juanatey JR; Moreno R; López-Sendón J; López-Fernández T
    Eur Heart J; 2024 Aug; ():. PubMed ID: 39106857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network.
    Nunes RAB; Neves PDMM; da Costa LMA; Bachour P; Cantarelli MJC; Oliveira GBF; Avezum Á
    Front Cardiovasc Med; 2023; 10():888366. PubMed ID: 36824461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.
    Cole AL; Wood WA; Muluneh B; Lund JL; Elston Lafata J; Dusetzina SB
    JCO Oncol Pract; 2020 May; 16(5):e443-e455. PubMed ID: 32196424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
    Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
    J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study.
    Yang YC; Huang RY; Tsai HJ; Li PC; Yang YH; Hsieh KP
    Eur J Prev Cardiol; 2022 Jul; 29(9):1312-1321. PubMed ID: 34179961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of nilotinib
    Yu L; Qin YZ; Lai YY; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):996-1002. PubMed ID: 32023729
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
    Petrikova L; Slezakova K; Sninska Z; Harvanova L; Martisova M; Hatalova A; Mistrik M; Batorova A; Mladosievicova B
    Bratisl Lek Listy; 2021; 122(8):531-537. PubMed ID: 34282617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment.
    Breccia M; Molica M; Zacheo I; Serrao A; Alimena G
    Ann Hematol; 2015 Mar; 94(3):393-7. PubMed ID: 25304102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
    Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
    [No Abstract]   [Full Text] [Related]  

  • 20. Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).
    Sicuranza A; Ferrigno I; Abruzzese E; Iurlo A; Galimberti S; Gozzini A; Luciano L; Stagno F; Russo Rossi A; Sgherza N; Cattaneo D; Zuanelli Brambilla C; Marzano C; Fava C; Mulas O; Cencini E; Santoni A; Sammartano V; Gozzetti A; Puccetti L; Bocchia M
    Front Oncol; 2022; 12():835563. PubMed ID: 35178353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.